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Abstract 
Background: Tetherin is an intrinsic anti-viral factor impairing the release of nascent HIV-1 particles from infected 
cells. Vpu, an HIV-1 accessory protein, antagonizes the anti-viral action of tetherin. Although previous studies using 
in vitro cell culture systems have revealed the molecular mechanisms of the anti-viral action of tetherin and the 
antagonizing action of Vpu against tetherin, it still remains unclear how Vpu affects the kinetics of HIV-1 replication 
in vivo.
Results: To quantitatively assess the role of Vpu in viral replication in vivo, we analyzed time courses of experimental 
data with viral load and target cell levels in the peripheral blood of humanized mice infected with wild-type and vpu-
deficient HIV-1. Our recently developed mathematical model describes the acute phase of this infection reasonably, 
and allowed us to estimate several parameters characterizing HIV-1 infection in mice. Using a technique of Bayesian 
parameter estimation, we estimate distributions of the basic reproduction number of wild-type and vpu-deficient HIV-
1. This reveals that Vpu markedly increases the rate of viral replication in vivo.
Conclusions: Combining experiments with mathematical modeling, we provide an estimate for the contribution of 
Vpu to viral replication in humanized mice.
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Findings
Tetherin is also known as bone marrow stromal antigen 
2 (BST2), CD317, and HM1.24, and impairs the release 
of a broad range of enveloped viruses including human 
immunodeficiency virus type 1 (HIV-1) by tethering bud-
ded virions on the surface of infected cells [1–3]. HIV-1 
expresses the accessory protein Vpu which antagonizes 
the anti-viral effect of tetherin [1–3]. Previous stud-
ies using in  vitro cell culture systems have revealed the 
molecular mechanisms of tetherin-mediated anti-viral 
effect and its antagonism by Vpu [3–5]. We have recently 
performed experiments using human hematopoietic 
stem cell-transplanted humanized mouse model infected 
with wild-type and vpu-deficient HIV-1 (HIV-1Δvpu [6, 
7]). These findings suggested that Vpu counteracts the 
anti-viral effect of tetherin in infected humanized mice, 
augmenting HIV-1 replication in  vivo [8]. We inves-
tigated and quantified the role of Vpu during the acute 
phase of infection using the humanized mouse model, 
which reasonably mimics HIV-1 infection in human 
before the onset of adaptive immune responses [8, 9].
To quantitatively understand the effect of Vpu on 
dynamics of viral replication and infection in  vivo, we 
here perform mathematical modeling of the experimen-
tal data published in [8]. Previously we simplified a “basic 
model” of virus infection [10, 11], to derive a novel model 
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that can be fitted to time course data from HIV-1 infected 
humanized mice and reliably estimate the parameters 
characterizing the dynamics of an acute infection (see 
Additional file 1) [12, 13]:
Here T (t) and V (t) are the densities of target cells and 
virus particles, respectively, at time t. The parameter β 
and δ are the rate constant for infection of target cells by 
virus and the death rate of virus producing cells, respec-
tively. The combined parameter r = pβ/c represents the 
viral replication rate per target cell, where p and c are the 
virus production rate of a virus producing cell and the 
clearance rate of virus particles, respectively. Thanks to 
this simplification the model has only 5 parameters. The 
novel model reasonably captures de novo infection pro-
cess, and these 5 parameters can be estimated more reli-
ably than the parameters of the previous models [14–16].
To quantitatively assess the effect of Vpu on viral spread 
in vivo, here we used the simplified model of Eqs. (1, 2), 
and applied this to time course data of the number of 
CD4+ T cells per ml of peripheral blood (PB) and the 
viral RNA load per ml of plasma of infected humanized 
mice [8]. We infected 9 and 10 humanized mice with 
CCR5-tropic wild-type (WT) HIV-1 (strain AD8) [17] 
and vpu-deficient HIV-1 (HIV-1Δvpu) [6, 18], respec-
tively, and 100 μl of PB was routinely collected at 0, 3, 7, 
14, and 21 days postinfection, as previously described [8, 
19–21]. The amount of viral RNA in 50 μl of plasma was 
quantified by real-time RT-PCR (Bio Medical Laborato-
ries, Inc). Since memory CD4+ T cells are the major pop-
ulation of target cells, their densities were measured by 
hematometry and flow cytometry as previously described 
[8, 19–21]. Briefly, the number of human leukocytes in 
10 μl of PB was measured by using a Celltac α MEK-6450 
(Nihon Kohden, Co.), and the percentage of memory 
CD4+ T cells (i.e., CD45+ CD3+ CD4+ CD45RA− cells; 
target cells) in human CD45+ leukocytes was analyzed by 
flow cytometry using a FACSCanto II (BD Biosciences).
Hereafter, we used the whole datasets from 9 WT 
(i.e., vpu-proficient) HIV-1-infected mice and 10 HIV-
1Δvpu-infected mice. To assess the variability of kinetic 
parameters (see Additional file 1), we performed Bayes-
ian estimation for the whole dataset using Markov Chain 
Monte Carlo (MCMC) sampling. To reduce the number 
of parameters, we allowed only the parameter r to vary 
between the two groups, and let all other parameters be 
shared between WT HIV-1 and HIV-1Δvpu-infected 








= rT (t)V (t)− δV (t).
terms of the measurement error of viral load among the 
mouse samples into the parameter estimation via MCMC 
computation (i.e., the variance of the error distribution to 
be minimized is not constant as is typically assumed in 
the nonlinear least square method, c.f., [22]). The dynam-
ics of target cells (i.e., memory CD4+ T cells) and viral 
load of WT HIV-1 and HIV-1Δvpu produced with the 
best fit parameter values are shown in Fig. 1a, c, respec-
tively. These results revealed that the Bayesian inference 
works well because the model describes the acute phase 
of WT HIV-1 and HIV-1Δvpu infections in humanized 
mice reasonably well (c.f. [12, 13]). The gray regions cor-
respond to 95 % posterior predictive intervals, the solid 
lines give the best-fit solution (mean) for Eqs.  (1, 2), 
and the black and orange dots with bars show the aver-
age data with the standard deviations. We summarized 
the kinetic parameters estimated by the Bayesian infer-
ence in Table  1. The marginal posterior distributions 
for each estimated parameter are shown in Additional 
file  2, together with scatter plots of paired parameters. 
Although the ranges of these posterior distributions were 
relatively narrows, they were not identifiable because 
r, δ, and T (0) correlate with one another. We also fitted 
our model to the individual data from each of the 9 and 
10 humanized mice infected with WT HIV-1 and HIV-
1Δvpu, respectively [using the FindMinimum package 
of Mathematica 9.0 to minimize the sum of squared 
residuals (see Additional files 2, 3, 5)]. Not surprisingly, 
this revealed that the two methods gave very consistent 
estimates for the parameters underlying WT HIV-1 and 
HIV-1 Δvpu infection in humanized mice.
To reduce the effects of the limited identifiability of r , 
δ , and T (0), we combined them into a single parameter 
R0 . The basic reproductive number R0 = rT (0)/δ is a well 
known quantity which is defined as the average number 
of newly infected cells produced from any one infected 
cell, under conditions where most of the target cells are 
uninfected [12, 13]. For the mice which had enough data 
to estimate the death rate of infected cells, we directly 
calculated R0 using individual estimation of T (0), r and 
δ. Additionally, we calculated R0 using the previously 
estimated mean death rate of δ = 0.6 per day (see Addi-
tional files 3, 4, 5). The average basic reproductive num-
ber of WT HIV-1 and HIV-1Δvpu in humanized mice 
is R0 = 2.09± 0.78 (mean± standard deviation) and 
1.72± 0.35, respectively. Interestingly, although vpu is 
not an essential gene for HIV-1 replication [8], we found 
that the average of the estimated R0 of WT HIV-1 tends 
to be somewhat greater than that of HIV-1Δvpu. We 
used all accepted MCMC parameter estimates from the 
whole datasets, and calculated that the mean values and 
the 95  % CIs of R0 for WT HIV-1 and HIV-1Δvpu are 
2.43 (95  % CI 1.78–3.26) and 2.25 (95  % CI 1.36–3.76), 
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respectively (see Table 1). The distributions of calculated 
R0 for WT HIV-1 and HIV-1 Δvpu are shown in Fig. 1b, 
d, respectively. Despite the small difference, the mean 
value of R0 for WT HIV-1 is significantly larger than that 
of that of HIV-1Δvpu (P < 0.01 by the repeated boot-
strap t test).
The retention of virion anchored by tetherin on the 
surface of infected cells should be reflected by the virus 
production rate, p, in the basic model (see [10, 11]). In 
addition to its effects on tetherin, Vpu degrades CD4 mol-
ecules on the surface of infected cells, and this function 
of Vpu is highly conserved in pandemic HIV-1 [4, 23–25]. 
The degradation of the viral receptor CD4 likely prevents 
aberrant interactions between newly synthesized CD4 
molecules and novel viral envelope glycoproteins in the 
endoplasmic reticulum of infected cells [26–29]. Hence 
Vpu is expected to increase the number of infectious 
particles produced per infected cell. We have recently 
shown that Vpu is closely associated with the down-mod-
ulation of CD4 molecules from the infected cells during 
the acute phase of infection in  vivo [8]. Therefore, one 
could argue that the infection rate β in the basic model 
also decreases in the absence of Vpu. It remains unclear 
whether this additional effect of Vpu plays a major quan-
titative role, but fortunately both effects are combined in 
the composed parameter r = pβ/c of our model. Hence, 
the difference in the estimated parameters, especially for 
the basic reproduction number (R0 = rT (0)/δ), between 
Fig. 1 Variability of virus dynamics and basic reproduction number in HIV-1 and HIV-1Δvpu infected humanized mice. The predicted variability of 
the dynamics of target cells (left) and viral loads (right) of WT HIV-1 (a) and HIV-1Δvpu (c) are shown based on Bayesian estimation for the whole 
datasets using MCMC sampling. The gray regions correspond to 95 % posterior predictive intervals. The solid lines give the best-fit solution for Eqs. (1, 
2), and the bullets with error bars show the average with standard deviations. Note that the initial viral loads are set at the detection limit for all sam-
ples. The distributions of calculated R0 from all accepted MCMC parameter estimates for WT HIV-1 and HIV-1Δvpu are shown in b and d, respectively. 
For each plot, the last 7000 MCMC samples among the total 10,000 samples are used
Table 1 Parameters values and derived quantities for the humanized mouse experiments by the Bayesian inference
† p = 0.138 by the repeated bootstrap t test and Cohen’s d = 0.664 (statistical power = 0.290) between WT HIV-1 and HIV-1Δvpu. 10 parameter sets are sampled from 
the posterior predictive distribution
‡ p = 0.035 by the repeated bootstrap t test and Cohen’s d = 1.395 (statistical power = 0.839) between WT HIV-1 and HIV-1Δvpu. 10 parameter sets are sampled from 
the posterior predictive distribution
Strain [best fit 
value (95 % CI)]









WT HIV-1 84,621 (66,301–105,897) 1324 (925–1837) 4.41 (2.58–6.78) 0.428 (0.261–0.699) 11.50 (7.79–16.84) 2.29 (1.75–2.90)
HIV-1Δvpu 9.97 (6.59–15.06) 1.97 (1.58–2.44)
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WT HIV-1 and HIV-1Δvpu infection reflects the overall 
role of Vpu in humanized mouse model.
In a previous study we compared the viral loads of WT 
HIV-1 with HIV-1Δvpu at different time points in bone 
marrow (BM) and spleen [8], and observed differences in 
the viral load only at the earliest time point in the spleen. 
The amount of cell-free virions in spleen is 100–10,000 
fold higher than that in BM [8]. These results suggest that 
the main source of viral particles in infected humanized 
mice is the spleen. This is in good agreement with the 
fact that we now establish that these two viruses differ 
in the replication rate, allowing a WT virus to approach 
the set-point viral load in the spleen at an earlier point 
in time. It could be that the set-point viral load is not 
strongly dependent on the replication rate (as set-points 
are also determined by innate immune responses and tar-
get cell availability), or that during chronic infection the 
virus replicates by cell-to-cell infection, which depends 
less on tetherin [8]. In addition, it is well known that the 
main target of HIV-1 infection is human CD4+ T cells 
and monocytes/macrophages. In this regard, we have 
previously reported that human CD4+ T cells are rela-
tively frequent in spleen, while monocytes/macrophages 
are more frequent in BM [19]. Since the current data 
were collected from the blood, we still do not understand 
why the approach to set-point is faster in the BM than in 
the spleen, in terms of kinetics. The evaluation of tissue-
specific effects of Vpu/tetherin on viral pathogenesis/rep-
lication requires further investigation, e.g., using a spatial 
model of viral replication [30].
To the best of our knowledge, this is the first report 
quantifying the role of Vpu in viral spread in  vivo. Our 
findings suggest that the ability of Vpu to down-regulate 
both tetherin and CD4 moderately increases HIV-1 repli-
cation during acute infection. Since the initial viral repli-
cative capacity plays an important role in the subsequent 
course of disease [31], this moderate increase could still 
have a large effect on the progression to AIDS.
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